10:05 Uhr
ROUNDUP 2: Nordkorea verkündet Aussetzung seiner Atom- und Raketentests

GenVec to Present at Phacilitate Cell & Gene Therapy World 2017

Mittwoch, 11.01.2017 14:05 von PR Newswire

PR Newswire

GAITHERSBURG, Md., Jan. 11, 2017 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced today that its chief scientific officer, Douglas E. Brough, will present a talk entitled  "AdenoVerse™ platform for translational development of innovative gene and cell therapies" during the Biotech Showcase at the upcoming Phacilitate Cell & Gene Therapy World 2017 Conference in Miami, Florida.  Dr. Brough's presentation will highlight the utility of the AdenoVerse technology platform for gene editing and cell therapy approaches as well as its potential to facilitate other gene-delivery based therapeutics and vaccines from the laboratory bench into the clinic.  Dr. Brough's presentation is scheduled for Wednesday, January 18, 2017 at 10:50 a.m. EST; and the slides will be posted at

About GenVec

GenVec is a clinical-stage gene delivery company focused on developing a pipeline of cutting-edge therapeutics and vaccines using its proprietary AdenoVerse platform. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product candidate, CGF166, is licensed to Novartis and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to its internal and partnered pipeline, the company is also focused on opportunities to license its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at and in the company's various filings with the Securities and Exchange Commission.


Rena Cohen 
(240) 632-5501


To view the original version on PR Newswire, visit:

SOURCE GenVec, Inc.